Fig. 2

30-day all-cause mortality in CAP or HAP patients, by risk factors and causative pathogen. Top panel. 30-day all-cause mortality in patients with CAP, by risk factor (CE population). Middle panel. 30-day all-cause mortality in patients with HAP (excluding VAP) by risk factor (CE population). Lower panel. 30-day all-cause mortality in high-risk group patients by pathogen type (CE population). ^aThe comparator treatment was ceftriaxone ± linezolid in CAP patients and ceftazidime plus linezolid in HAP (excluding VAP) patients. ^bBetween treatment difference calculated as ceftobiprole minus comparator. ^cTwo-sided 95% confidence interval is based on a normal approximation to the difference of the two proportions